within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD12_PioglitazoneAndSitaglipt;

model PioglitazoneAndSitaglipt
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 9.722222222222222e-07,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.038,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0016666666666666668,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>PioglitazoneAndSitagliptin</td></tr><tr><td>ATC code:</td><td>A10BD12</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>38</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pioglitazone and sitagliptin is a fixed-dose combination of an oral antidiabetic thiazolidinedione (pioglitazone) and a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) used in the management of type 2 diabetes mellitus. Pioglitazone increases insulin sensitivity, while sitagliptin enhances incretin hormone levels, leading to improved glycemic control. This combination is approved in several countries for use as part of a comprehensive diabetes treatment regimen.</p><h4>Pharmacokinetics</h4><p>Estimated composite pharmacokinetic parameters for healthy adult subjects, based on published data for individual drugs (pioglitazone and sitagliptin), as no specific published population pharmacokinetic models for the fixed-dose combination were located.</p><h4>References</h4><ol><li><p>Kadokura, T, et al., &amp; Smulders, R (2014). Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. <i>Clinical pharmacokinetics</i> 53(11) 975–988. DOI:<a href=\"https://doi.org/10.1007/s40262-014-0180-z\">10.1007/s40262-014-0180-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25316572/\">https://pubmed.ncbi.nlm.nih.gov/25316572</a></p></li><li><p>Scheen, AJ (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. <i>Drugs</i> 75(1) 33–59. DOI:<a href=\"https://doi.org/10.1007/s40265-014-0337-y\">10.1007/s40265-014-0337-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25488697/\">https://pubmed.ncbi.nlm.nih.gov/25488697</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BD12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end PioglitazoneAndSitaglipt;
